However, although the advent of ICIs has revealed novel therapies for ccRCC, only a subset of individuals would benefit from the current PD-1, PD-L1, and CTLA-4 inhibitors due to no-response and resistance in RCC patients7. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.